Screen Reader Access
Dr. Shashank Kr. Singh
Sr. Principal Scientist
Pharmacology Division
CSIR – Indian Institute of Integrative Medicine,Canal Road, Jammu – 180001
Email: sksingh[at]iiim[dot]res[dot]in
Bio Sketch
Research and Development:
- Responsible role in Cancer Pharmacology Division looking after the in vitro /in vivo oncology R&D platform.
- Engaged in Discovery Pharmacology to supports the development of molecules (natural product/semisynthetic and small molecules) inhibitors for (oncology and immunooncology areas) and investigates their benefit in combination with the standard-alone drugs using in vitro/ex vivo assays and xenograft/humanized in vivo models.
- Supporting in development of formulation of lead candidates which have PK liabilities
Core research competency:
- In vitro cell-based screening against NCI60 panel of Human cancer cell lines for preliminary profiling of compounds using SRB assay.
- Molecule (natural product/semisynthetic and small molecules) inhibitors of cancer targets.
- Anti-cancer Drug Combination studies for developing synergistic combinations using mathematical models and isobolograms.
- Preclinical in vitro and in vivo drug mechanistic studies in colon, pancreatic, oral and breast tumor models.
Established biochemical assays for battery of kinases (i.e EGFR.PI3K, AKT,mTOR, CDKs) and establishing few IO targets.
Education
| Degree | Subjects | University | Qualifying Year |
| Ph.D | Pharmaceutical Sciences | Faculty of Pharmacy,
University of Delhi, New Delhi |
2003-2009 |
| M. Pharm | Pharmacy | Faculty of Pharmacy,
BITS, Pilani, Rajasthan |
1999-2000 |
| B. Pharm | Pharmacy | Department of Pharm. Sci.
Dr. H.S.G. Central University , Sagar, MP |
1994-1998 |
Position Held
| Position Held | Period | Organization |
| Sr. Principal Scientist | Dec 2020-Present | CSIR-IIIM,Jammu |
| Principal Scientist | Dec 2010-Dec 2014 | CSIR-IIIM,Jammu |
| Senior Scientist | Dec2006- Dec 2010 | CSIR-IIIM, Jammu |
| Indo-US Fellow | Sept 2009 – July 2010 | Medical Center, Ohio State University, USA |
| Scientist | Dec 2003 to Dec 2006 | CSIR-IIIM, Jammu |
| Scientist B | Dec 2003 | RRL, Jammu |
| Research Associate | April 2001 to Sept2001 | R&D Centre, Win-Medicare Ltd, (subsidiary of Winthrop, USA) Modipuram, Meerut UP |
| Research Associate | July 2000 to April 2001 | Process Validation,
M/s Cadila Pharmaceuticals Ltd. Ahmedabad (Guj.) |
Area of Expertise
- In vitro and in vivo Mechanistic studies of anticancer molecules.
- Target based screening of chemical libraries for cancer.
- Formulation development of preclinical leads to overcome the PK liabilities.
Projects
- Targeting signaling pathways for anti-cancer drug discovery: Inhibition of PI3K/Akt/mTOR signaling pathway for anti-cancer drug discovery (CSIR-RC approved Project)
- SNP based tumour profiling and individualization of chemotherapy combination(s) using chemo sensitivity in oral cancer (DST).
- Development of IIIM-368 as a potent CDK inhibitor for the treatment of cancer :Studies towards preclinical investigation (ICMR).
- Synthetic lethal interactions with oncogenic KRAS in establishing a comprehensive resource for immunogenic drug sensitivity in Colon cancer therapy.
Publications
| Authors | Title | Journal |
| Venu Sharma , Arem Qayum , Sanjana Kaul , Ajeet Singh , Kamal K Kapoor , Debaraj Mukherjee , S K Singh , Manoj K Dhar | Carbohydrate Modifications of Neoandrographolide for Improved Reactive Oxygen
Species-Mediated Apoptosis through Mitochondrial Pathway in Colon Cancer.
|
ACS Omega, . 2019 Nov 26;4(24):20435-20442.
doi: 10.1021/acsomega.9b01249. |
| Nidhi Gupta , Arem Qayum , Arun Raina , Ravi Shankar , Sumeet Gairola S. Singh , Payare L Sangwan | Synthesis and biological evaluation of novel bavachinin analogs as anticancer agents
|
Eur J Med Chem . 2018 Feb 10;145:511-523. doi: 10.1016/j.ejmech.2018.01.006. Epub 2018 Jan 8. |
| Singh I, Singh S, Verma V, Uversky VN, Chandra R. | In silico evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib. | J Biomol Struct Dyn. 2017 Dec 11:1-11. doi: 10.1080/07391102.2017.1411293. [Epub ahead of print] PubMed PMID: 29183267. |
| Hussain A, Qazi AK, Mupparapu N, Guru SK, Kumar A, Sharma PR, Singh SK, Singh P, Dar MJ, Bharate SB, Zargar MA, Ahmed QN, Bhushan S, Vishwakarma RA, Hamid A. | Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth. | Cancer Lett. 2016 1;374(2):250-60.doi: 10.1016/j.canlet.2016.02.030. Epub 2016 Feb 23. PubMed PMID: 26921131. |
| Khare V, Dubey R, Alam N, Saneja A, Gupta PN, Singh SK. | Synthesis of PLGA-gemcitabine conjugate and its anti-proliferative properties. | J Control Release. (2015) Sep 10;213:e107. doi: 10.1016/j.jconrel.2015.05.179. Epub 2015 Aug 19. PubMed PMID: 27005036. |
| Qazi AK, Hussain A, Khan S, Aga MA, Behl A, Ali S, Singh SK, Taneja SC, Shah BA, Saxena AK, Mondhe DM, Hamid A. | Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer. | Cancer Lett. 2015 Apr 1;359(1):47-56. doi: 10.1016/j.canlet.2014.12.034. Epub 2014 Dec 29. PubMed PMID: 25554016. |
| Majeed R, Hamid A, Sangwan PL, Chinthakindi PK, Koul S, Rayees S, Singh G,Mondhe DM, Mintoo MJ, Singh SK, Rath SK, Saxena AK. | . Inhibition of phosphotidylinositol-3 kinase pathway by a novel naphthol derivative of betulinic acid induces cell cycle arrest and apoptosis in cancer cells of different origin
|
. Cell Death Dis. 2014 Oct 9;5:e1459. doi: 10.1038/cddis.2014.387. PubMed PMID: 25299784; PubMed Central PMCID: PMC4237233. |
| Pandita A, Kumar B, Manvati S, Vaishnavi S, Singh SK, Bamezai RN. | Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression. | PLoS One. 2014 Sep 8;9(9):e107154. doi: 10.1371/journal.pone.0107154. eCollection 2014. PubMed PMID: 25197966; PubMed Central PMCID: PMC4157832.
|
| Mukherjee A, Hazra S, Dutta S, Muthiah S, Mondhe DM, Sharma PR, Singh SK, Saxena AK, Qazi GN, Sanyal U. | Antitumor efficacy and apoptotic activity of substituted chloroalkyl 1H-benz[de]isoquinoline-1,3-diones: a new class of potential antineoplastic agents.
|
Invest New Drugs. 2011 Jun;29(3):434-42. doi: 10.1007/s10637-009-9372-z. Epub 2010 Jan 12. PubMed PMID: 20066471. |
| Singh SK, Bhusari S, Singh R, Saxena A, Mondhe D, Qazi GN. | Effect of acetyl 11-keto beta-boswellic acid on metastatic growth factor responsible for angiogenesis. | Vascul Pharmacol. 2007 May;46(5):333-7. Epub 2006 Nov 10. PubMed PMID: 17257903. |
Patents
| Inventors/ Contributors | Title | Description | Year |
| Ahmed Kamal, Yellamelli Valli Venkata Srikanth, Mohammed Naseer Ahmed KHAN, Mohammed Ashraf, Irum Sehar Gousia Chashoo, Parduman Raj Sharma,Abid Hamid Dar, Bhushan Shashi,Shashank Kumar Singh, Dilip Manikrao Mondhe, Ajit Kumar Saxena | “2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof” | US Patent no. US9029553 B2 | ( Granted : 2015)
|
| Ghulam Nabi Qazi, Ajit Kumar Saxena,Shanmugavel Muthiah, Dilip Manikrao Mondhe, Parduman Raj Sharma, Shashank Kumar Singh, Utpal Sanyal, Asama Mukherjee, Suva Hazra, Susanta Dutta | Substituted 1H-benz[de]isoquinoline-1,3-diones.
|
EU Patent no. EP2118065 B1 | (Granted :2013).
|
| Ghulam Nabi Qazi, Subhash Chandra Taneja,Jaswant Singh, Ajit Kumar Saxena, Vijay Kumar Sethi, Bhahwal Ali Shah, Bal Krishan Kapahi, Samar Singh Andotra, Ajay Kumar,Shashi Bhushan, Fayaz Malik, Dilip Manikrao Mondhe, Shanmugavel Muthiah, Surjeet Singh, Monika Verma, Shashank Kumar Singh, | Use of semi synthetic analogues of boswellic acids for anticancer activity , | US Patent US20090298938 A1 | (Granted 2009).
|
| Qazi ,Ghulam Nabi.; Taneja, Subhash Chandra.;Singh, Jaswant.; Saxena, Ajit Kumar.; Sethi, Vijay Kumar.; Shah, Bhahwal Ali.; Kapahi ,Bal Krishan.;Andotra, Samar Singh.; Kumar, Ajay.; Bhishan, Shashi.; Malik ,Fayaz.; Mondhe, DilipManikarao.; Shanmugavel,Muthiah.; Singh ,Surjeet.; Verma, Monika.; Singh, Shashank Kumar,; | Cytotoxicity And Indusction Of Apoptosis In Cancer Cells By Semi-Synthetic Analogues Of Boswellic Acids For Their Use As Anti-Cancer Agents
|
(US Patent No US20090298938 A1 | (Granted :2009) |
| Qazi ,Ghulam Nabi.; Saxena, Ajit Kumar.; Muthiah ,Shanmugavel.; Mondhe Dilip,Manikrao.; Sharma, Praduman Raj.; Singh, Shashank Kumar.; Utpal,Sanyal.; Mukherjee, Asama.; Hazra ,Suva.; Dutta ,Sushanta.; | Novel Substituted 1h-Benz[De]Isoquinoline-1,3-Diones As Anticancer Agents .
|
WO Patent WO2008084496 A1 | (Granted :2008) |
| MSK Halmuthur, AK Saxena, SC Taneja, SK Singh, VK Sethi, NA Qazi | Spiro derivatives of parthenin as novel anticancer agents | US Patent 8,609,858 12013
|
(Granted :2011) |
Awards and Honours
Recipient of Indo-US Research Fellowship 2009 from Indo-US Science Technology Forum (IUSSTF), New Delhi to pursue advanced research in the area of cancer drug mechanistic studies at Ohio State University, Columbus, Ohio USA.
Students
Doctoral Fellows
| Photo | Name | Area of Interest | Position |
 |
Ms. Sonia Thapa | She is working on potential application of endocannabinoid system (ECS) agents, acting as neuro-protective entities, particularly, by activating Cannabinoid receptor 1(CB1R) in neuron-like cells, to prevent neuropathic pain and neuroinflammation in various neurodegenerative diseases. Her main focus is, the activation of Cannabinoid receptor 1 (CB1R), its precise molecular mechanism and therapeutic potential assessment in neuroprotection. | UGC-SRF |
 |
Ms Rafia Basit | She is currently working on the Combination Studies of Meriolin Derivatives (a cyclin dependent protein kinase inhibitor) with known Cytotoxic Agents against Lung cancer”. She is working on the novel synergistic combination between a novel CDK inhibitor (Meriolin) and a chemotherapeutic drug in order to combat lung cancer. | ICMR-SRF |
 |
Ms. Manmeet kour | She is working on mechanistic elucidation of target selective modulation of cancer cell properties for possible therapeutics. Therapeutic potential of novel compounds in cancer by targeting major signaling pathways in cancer. | DST-Inspire |
 |
Mr. Ajeet Singh | Working on pharmacological aspects of cannabinoid receptor and their ligand in cancer therapeutics .Studying the regulation of the CB2 receptor pathway with its agonist/antagonist individually or in combination (combination with other cannabinoid or other pharmacological active compound which regulates the downstream proteins of cannabinoid pathway) for their anticancer potential and anticancer immunity. | DBT-SRF |
 |
Ms. Shabu Thakur | Working on endophytic fungi and bacterial cultures for discovering active corallococcus coralloids bacteria metabolites against human cancers. | ICMR-JRF |
 |
Mr. Tenzen Yodun | Working on plant derived natural and semi-synthetic molecules. The primary focus is discovering a potent anticancer molecule(s) to target a specific signalling pathways in cancer. | CSIR-JRF |
| Post Doctoral Fellows |  |
Dr. Gousia Chashoo | She is currently working as Young Scientist (ICMR) project “Development of IIIM-368 as a potent CDK inhibitor for the treatment of cancer :Studies towards preclinical investigation” at under my mentorship. She does research on evaluating CDKs in cancer therapy. | Young Scientist (ICMR) |
 |
Dr. Arem Qayum | She is currently working as ICMR Research Associate on project Synthetic lethal interactions with oncogenic KRAS in establishing a comprehensive resource for immunogenic drug sensitivity in Colon cancer therapy. | ICMR Research Associate |